|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2002-11-19
|
|
pubmed:abstractText |
The endothelin (ET-1) system is activated in chronic heart failure (CHF). Whether, what type, and what degree of selective ET blockade is clinically beneficial is unknown. We investigated hemodynamic and neurohumoral effects of 3 weeks of treatment with various dosages of the orally available ET(A) antagonist darusentan in addition to modern standard therapy in patients with CHF.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:author |
pubmed-author:DietzRainerR,
pubmed-author:EnseleitFrankF,
pubmed-author:HürlimannDavidD,
pubmed-author:Heart Failure ET(A) Receptor Blockade Trial,
pubmed-author:LüscherThomas FTF,
pubmed-author:MitrovicVeselinV,
pubmed-author:NollGeorgG,
pubmed-author:NotterThomasT,
pubmed-author:PacherRichardR,
pubmed-author:PhilippSebastianS,
pubmed-author:RoussonValentinV,
pubmed-author:RuschitzkaFrankF,
pubmed-author:SchulzeMatthias RMR,
pubmed-author:WillenbrockRolandR
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2666-72
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:articleTitle |
Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).
|
|
pubmed:affiliation |
Cardiovascular Center, Cardiology, University Hospital, Zürich, Switzerland. cardiotfl@gmx.ch
|
